Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The role of endogenous androgens and sex hormone-binding globulin (SHBG) in ovarian carcinogenesis is poorly understood. Epithelial invasive ovarian cancer (EOC) is a heterogeneous disease and there are no prospective data on endogenous androgens and EOC risk by tumor characteristics (histology, grade, stage) or the dualistic model of ovarian carcinogenesis (i.e. type I vs. type II, leading to less or more aggressive tumors). We conducted a nested case-control study in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort evaluating androgens and SHBG and invasive EOC risk by tumor characteristics. Female participants who provided a blood sample and were not using exogenous hormones at blood donation were eligible (n = 183,257). A total of 565 eligible women developed EOC; two controls (n = 1,097) were matched per case. We used multivariable conditional logistic regression models. We observed no association between androgens, SHBG and EOC overall. A doubling of androstenedione reduced risk of serous carcinomas by 21% (odds ratio (OR)log2 = 0.79, 95% confidence interval [CI] = [0.64-0.97]). Moreover, associations differed for low-grade and high-grade carcinomas, with positive associations for low-grade and inverse associations for high-grade carcinomas (e.g. androstenedione: low grade: ORlog2 = 1.99 [0.98-4.06]; high grade: ORlog2 = 0.75 [0.61-0.93], phet ≤ 0.01), similar associations were observed for type I/II tumors. This is the first prospective study to evaluate androgens, SHBG and EOC risk by tumor characteristics and type I/II status. Our findings support a possible role of androgens in ovarian carcinogenesis. Additional studies exploring this association are needed.

Original publication

DOI

10.1002/ijc.29000

Type

Journal article

Journal

Int J Cancer

Publication Date

15/01/2015

Volume

136

Pages

399 - 410

Keywords

androstenedione, endogenous androgens, histologic subtype, ovarian carcinoma, type I tumors, type II tumors, Adult, Aged, Aged, 80 and over, Androgens, Case-Control Studies, Cystadenocarcinoma, Serous, Europe, Fallopian Tube Neoplasms, Female, Follow-Up Studies, Humans, Middle Aged, Neoplasm Grading, Neoplasm Invasiveness, Neoplasm Staging, Neoplasms, Glandular and Epithelial, Nutritional Status, Ovarian Neoplasms, Peritoneal Neoplasms, Prognosis, Prospective Studies, Risk Factors, Sex Hormone-Binding Globulin